SpringWorks Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| SpringWorks Therapeutics, Inc. | SWTX - NASDAQ |
$16.00-$18.00 | $18.00 | $24.50 | 9.0 million | 9/13/2019 |
| JP Morgan, Goldman Sachs, Cowen | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-08-16 Terms Added 2019-09-13 Amended Terms 2019-09-12 | ||||||
SpringWorks Therapeutics, Inc. Quote & Chart - Click for current quote - SWTX
IPO Boutique aggregates information on public companies and private companies, such as "SWTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About SpringWorks Therapeutics, Inc. (adapted from SpringWorks Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "SWTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.